Related Experiment Video

Updated: Apr 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

AhR expression and polymorphisms are associated with risk of coronary arterial disease in Chinese population

Shian Huang1, Xiaorong Shui2, Yuan He3

  • 11] Laboratory of Cardiovascular Diseases, Guangdong Medical College, Zhanjiang 524001, China [2] Department of Cardiovascular Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China.

Scientific Reports
|January 27, 2015
PubMed

Insights

Increased aryl hydrocarbon receptor (AhR) expression and specific variants are linked to coronary arterial disease (CAD) susceptibility and progression in Chinese populations. AhR may serve as a biomarker for CAD diagnosis and therapy.

Area of Science:

  • Cardiovascular Biology
  • Environmental Toxicology
  • Human Genetics

Background:

  • The aryl hydrocarbon receptor (AhR) is a key mediator of environmental toxicity.
  • AhR plays a role in cardiovascular system development and pathogenesis.
  • The specific role of AhR in coronary arterial disease (CAD) susceptibility remains largely unknown.

Purpose of the Study:

  • To investigate the association between aryl hydrocarbon receptor (AhR) variants and coronary arterial disease (CAD) susceptibility in a Chinese population.
  • To evaluate circulating AhR expression as a potential biomarker for CAD.
  • To explore the relationship between AhR polymorphisms and CAD subtypes.

Main Methods:

  • A case-control study was conducted in a Chinese population.
  • Circulating AhR expression levels were measured and compared between CAD patients and controls.
  • Genotype frequencies of AhR rs2066853 were analyzed.
  • Receiver operating characteristic (ROC) analysis was performed to assess AhR's biomarker potential.

Main Results:

  • Circulating AhR expression was significantly elevated in CAD patients and various CAD subtypes compared to controls.
  • AhR rs2066853 genotype frequencies differed significantly between CAD cases and controls.
  • Smoking and hyperlipidemia were identified as significant risk factors for CAD, interacting with AhR polymorphism.
  • Distinct AhR variant distributions were observed across different CAD severity subtypes.

Conclusions:

  • Circulating AhR expression levels and functional polymorphisms are associated with CAD susceptibility and progression in Chinese individuals.
  • AhR may serve as a potent biomarker for CAD diagnosis and a therapeutic target.
  • These findings offer a novel perspective on the etiology and epidemiology of CAD.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
17.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98